NOTABLE PUBLICATIONS
RILEY HEART CENTER
30-day Survival: 2022 – 2024
The cardiovascular surgeons at Riley Children’s Health treat and manage the full spectrum of heart defects—from the most common to the most rare and complex. Practicing at the highest level of board certification, our heart surgeons offer a degree of expertise found only in the most advanced pediatric hospitals. CARDIOTHORACIC SURGERY
Index operations †
All operations
World Journal for Pediatric and Congenital Heart Surgery: January 2025 Twenty-seven-year institutional experience with surgery for adults with congenital heart disease JTCVS Open: July 2024 Autonomous Fontan pump: Computational feasibility study Lead author: Mark D. Rodefeld, MD World Journal for Pediatric and Congenital Heart Surgery: February 2025 Conduit size, branch pulmonary artery size, and reoperation in patients with truncus arteriosus World Journal for Pediatric and Congenital Heart Surgery: January 2025 Prospective evaluation of extubation failure in neonates and infants after cardiac surgery
97%
93%
2022
99% 98%
96% 96%
2023
2024
† The first cardiac operation of a hospitalization
Premier programs
TOP DISTINCTIONS
Postoperative Overall Complications The Society of Thoracic Surgeons (STS) Participant Dashboard for period July 1, 2020 – June 30, 2024
■ Treats more infants, children and teenagers with heart conditions than any other institution in Indiana ■ Exceptional heart transplant outcomes – One-year patient survival remains at 100%; exceeds the national average. * – Fontan patients with cirrhosis: One- and three-year orthotopic heart transplant (OHT) survival in our biopsy-proven cirrhosis group is 100%; one- and three-year OHT survival in our imaging-proven cirrhosis group is 100% and 91%, respectively. ** – Our surgeons are performing more transplants for patients with neonatal Marfan’s syndrome. ■ Only pediatric and adult congenital transplant program in Indiana; program accredited by the Adult Congenital Heart Association ■ Seven decades of experience with right ventricular outflow tract reconstruction
■ Cardiovascular Genetics Program ■ Aortopathy Program ■ Adult Congenital Heart Disease Program ■ Cardiac Rehabilitation Program ■ Single Ventricle Home Monitoring Program ■ Ventricular Assist Device Home Monitoring Program ■ Fontan Program
No complications identified Riley Children’s 56.93%
STS overall 53.49%
One or more complications identified
Riley Children’s 43.07%
STS overall 46.04%
Our surgeons are able to minimize cross-clamp time and in nearly all categories achieve less time on bypass than the national average.
Median CPB and Cross Clamp Time for Select Procedures (in minutes) ††
Mark W. Turrentine, MD , was one of the first surgeons in the United States to use the Berlin Heart to manage a child in heart failure. His efforts were instrumental in getting approval from the FDA.
Advanced therapies and procedures
■ Dedicated simulation lab that includes training on ventricular assist devices ■ Only program in Indiana offering the Berlin Heart for children
CPB TIME
RILEY CHILDREN’S
STS
AV Canal Partial
64 72
81 96
Intermediate
103.5
139
Complete
Operative and Adjusted Operative Mortality***
62
76
VSD
EXPECTED MORTALITY RILEY CHILDREN’S
OBSERVED MORTALITY RILEY CHILDREN’S
NEONATES/INFANTS/ CHILDREN/ADULTS
STS OVERALL
58
107
Valvuloplasty
147.5
164
Norwood
All STAT Mortality Categories STAT Category 1 (Least risk)
3.39%
3.72%
2.65%
CROSS-CLAMP TIME
RILEY CHILDREN’S
STS
AV Canal Partial
DIVISION CHIEF Mark W. Turrentine, MD John W. Brown Professor of Cardiothoracic Surgery, IU School of Medicine United Network for Organ Sharing primary surgeon > Connect with Dr. Turrentine on Doximity.
0.60%
0.66%
0.60%
41 46 68 35
56 69
Intermediate
2.06%
1.58%
2.05%
STAT Category 2
105
Complete
4.23%
4.72%
3.26%
STAT Category 3
50
VSD
9.54%
7.85%
7.74%
STAT Category 4
35
75
Valvuloplasty
3 board certified physicians
STAT Category 5 (Most risk)
See full team member list >
** Source: Parent J, Markham L, Darragh R, et. al. Fontan heart transplant with cirrhosis: Give the liver to someone that needs it. The Journal of Heart and Lung Transplantation. April 2025 * Source: Scientific Registry of Transplant Recipients (SRTR) Table C19D, released July 2025 for period January 1, 2022 – June 30, 2024
19.22%
35.00%
15.29%
47
71
Norwood
Note: Per STS, observed mortality is as expected based on institution’s case mix. *** Source: Society of Thoracic Surgeons (STS) Table 16, Harvest Report, published December 2024 for period ending June 30, 2024
†† Source: Society of Thoracic Surgeons (STS) Harvest Report, published December 2024 for period ending June 30, 2024
Annual Report 2024 – 2025
Refer a patient online
317.944.7150
Made with FlippingBook flipbook maker